January 14, 2020

Irene Getty
Chief Financial Officer
Peptide Technologies, Inc.
5348 Vegas Drive #177
Las Vegas, NV 89108

       Re: Peptide Technologies, Inc.
           Form 10-K for the Fiscal Year Ended March 31, 2019
           Filed June 24, 2019
           File No. 000-53230

Dear Ms. Getty:

       We have reviewed your filing and have the following comments. In some of
our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.

       Please respond to these comments within ten business days by providing
the requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comments apply to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to these comments, we may have additional
comments.

Form 10-K for Fiscal Year Ended March 31, 2019

Item 9A. Controls and Procedures, page 24

1.    Please amend your Form 10-K to provide all disclosures required by Item
308 of
      Regulation S-K. As required by Item 308(a)(2), provide a statement
identifying the
      framework used by management to evaluate the effectiveness of your
internal control over
      financial reporting. Pursuant to Item 308(a)(3), provide management's
conclusion
      regarding the effectiveness of your internal control over financial
reporting, including a
      statement as to whether or not internal control over financial reporting
was effective. We
      remind you that management is not permitted to conclude that internal
control over
      financial reporting is effective if there are one or more material
weaknesses in your
      internal control over financial reporting. You may provide an abbreviated
amendment that
      includes a cover page, explanatory note, the complete text of Item 9A, a
signature page
      and the certification required by Item 601(b)(31) of Regulation S-K,
including paragraphs
      1,2,4 and 5.
 Irene Getty
Peptide Technologies, Inc.
January 14, 2020
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       You may contact Tracie Mariner, Staff Accountant, at (202) 551-3744, or
Jeanne Baker,
Staff Accountant, at (202) 551-3691, if you have questions regarding comments
on the financial
statements and related matters.



FirstName LastNameIrene Getty                             Sincerely,
Comapany NamePeptide Technologies, Inc.
                                                          Division of
Corporation Finance
January 14, 2020 Page 2                                   Office of Life
Sciences
FirstName LastName